These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7644776)

  • 1. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.
    Ukena D; Rentz K; Reiber C; Sybrecht GW
    Respir Med; 1995 Jul; 89(6):441-4. PubMed ID: 7644776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma.
    Brunnée T; Engelstätter R; Steinijans VW; Kunkel G
    Eur Respir J; 1992 Sep; 5(8):982-5. PubMed ID: 1426207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease.
    Imhof E; Elsasser S; Karrer W; Grossenbacher M; Emmons R; Perruchoud AP
    Respiration; 1993; 60(2):84-8. PubMed ID: 8341859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.
    Myou S; Fujimura M; Kamio Y; Ishiura Y; Tachibana H; Hirose T; Hashimoto T; Matsuda T
    Am J Respir Crit Care Med; 1999 Sep; 160(3):817-20. PubMed ID: 10471602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
    Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
    Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
    Campbell S
    Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchodilator response to nebulized salbutamol in elderly patients with stable chronic airflow limitation.
    Geraghty R; Foster C; Black D; Roe S
    Respir Med; 1993 Jul; 87(5):375-8. PubMed ID: 8209057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
    Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
    J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease.
    Wempe JB; Postma DS; Breederveld N; Kort E; van der Mark TW; Koëter GH
    Thorax; 1992 Aug; 47(8):616-21. PubMed ID: 1412119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia.
    Bar-Aluma BE; Efrati O; Kaufmann H; Palma JA; Norcliffe-Kaufmann L
    Lung; 2018 Feb; 196(1):93-101. PubMed ID: 29234869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
    van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
    Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zardaverine as a selective inhibitor of phosphodiesterase isozymes.
    Schudt C; Winder S; Müller B; Ukena D
    Biochem Pharmacol; 1991 Jun; 42(1):153-62. PubMed ID: 1648920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease.
    Burdet L; de Muralt B; Schutz Y; Fitting JW
    Thorax; 1997 Feb; 52(2):130-5. PubMed ID: 9059472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
    Cazzola M; Calderaro F; Califano C; Di Pema F; Vinciguerra A; Donner CF; Matera MG
    Eur J Clin Pharmacol; 1999 Jan; 54(11):829-33. PubMed ID: 10027655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease.
    Ikeda A; Nishimura K; Koyama H; Tsukino M; Hajiro T; Mishima M; Izumi T
    Respiration; 1999; 66(2):119-23. PubMed ID: 10202314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.
    Steffensen I; Faurschou P; Riska H; Rostrup J; Wegener T
    Allergy; 1995 Aug; 50(8):657-63. PubMed ID: 7503401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.
    Bel EH; Zwinderman AH; Timmers MC; Dijkman JH; Sterk PJ
    Thorax; 1991 Jan; 46(1):9-14. PubMed ID: 1871705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.